NCT01777139View on ClinicalTrials.gov

A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 11, 2013

Primary Completion Date

December 14, 2016

Study Completion Date

September 13, 2017

Conditions
Epilepsy
Interventions
DRUG

Retigabine IR

Retigabine IR tablets will be available in 5 strengths: 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.

Trial Locations (12)

10400

GSK Investigational Site, Bangkok

40002

GSK Investigational Site, Khon Kaen

59100

GSK Investigational Site, Kuala Lumpur

602-715

GSK Investigational Site, Busan

612-865

GSK Investigational Site, Busan

700-712

GSK Investigational Site, Daegu

301-721

GSK Investigational Site, Daejeon

463-707

GSK Investigational Site, Gyeonggi-do

110-744

GSK Investigational Site, Seoul

135-720

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Seoul

143-729

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01777139 - A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures | Biotech Hunter | Biotech Hunter